Basket, Umbrella, and Platform Trials: What Master Protocols Actually Do

A master protocol is a single overarching study framework that runs several substudies at the same time, letting investigators evaluate one or more therapies across one or more diseases under shared infrastructure and oversight. The three common forms answer different questions. A basket trial tests one drug across many diseases that share a molecular feature. An umbrella trial tests many drugs within one disease, sorting patients by biomarker. A platform trial runs continuously, adding and dropping treatment arms over time against a common control. Tissue-agnostic approvals, where a drug is cleared by a genetic marker rather than the organ, grew out of the basket design.

The U.S. Food and Drug Administration codified this taxonomy in its final oncology guidance, "Master Protocols: Efficient Clinical Trial Design Strategies To Expedite Development of Oncology Drugs and Biologics," made available in early 2022 through the agency's drug and biologics centers. In December 2023 the FDA published a broader draft guidance, "Master Protocols for Drug and Biological Product Development," extending the same principles beyond cancer, with a public comment period that ran into 2024. A draft is not settled policy, so the 2023 document should be read as the agency's proposed thinking rather than a fixed rule. What both documents share is a definition: a master protocol coordinates multiple substudies within one structure, and that shared structure is what makes a shared control arm, shared screening, and shared safety monitoring possible.

Why the shared skeleton matters

The efficiency of a master protocol is structural rather than a statistical trick. Running separate trials for each drug or each disease means rebuilding the same machinery every time: a new protocol, a new set of sites, a new control group, a fresh regulatory submission. A master protocol builds that skeleton once. New questions attach to it as substudies. That is why the FDA frames these designs as a way to expedite development, and it is also why the design demands discipline. When many substudies share one framework, a change to the framework touches everything, and a weak control arm or a loose statistical plan can contaminate several comparisons at once.

Basket trials: one drug, many diseases

A basket trial starts from a target rather than an organ. If a mutation, fusion, or protein appears in lung, colon, thyroid, and pancreatic tumors alike, a basket trial enrolls all of them into parallel cohorts, or "baskets," and gives each the same targeted drug. The scientific bet is that the target matters more than the tissue of origin. This is the design that produced the first tissue-agnostic approvals. In 2017 the FDA approved pembrolizumab for solid tumors that are microsatellite instability-high or mismatch-repair deficient, the first time the agency cleared a cancer therapy defined by a biomarker rather than a body part. In late 2018 larotrectinib followed, granted accelerated approval for solid tumors carrying an NTRK gene fusion, based on multi-cohort single-arm trials that enrolled patients across roughly a dozen tumor types. The direction of those results, with responses concentrated in the biomarker-positive population, is what supported an approval untethered from any single cancer site.

Basket trials carry a specific hazard: the same target can behave differently in different tissues. A drug that shrinks tumors in one organ may do little in another despite the shared mutation. That is why the FDA's guidance stresses adequate cohort sizes and pre-specified rules, so a real signal in one basket is not diluted or masked by pooling.

Umbrella trials: one disease, many drugs

An umbrella trial inverts the logic. It takes a single disease, say non-small cell lung cancer, and splits patients by their molecular subtype, then assigns each subtype the drug matched to it. One umbrella can hold several experimental arms under one roof, with shared eligibility screening feeding patients into the arm that fits their biomarker. The appeal is clear for diseases that fracture into many rare molecular subsets: instead of a dozen small, slow trials, one structure screens everyone and routes them. The FDA's 2023 draft guidance gives particular attention to umbrella and platform designs, because these are where the questions of shared controls and comparisons between experimental arms become most delicate.

Platform trials: an ongoing structure

A platform trial is an umbrella that never formally closes. Arms enter as new candidates become ready and leave when a decision is reached, all measured against a common, often shared, control group that persists across the life of the trial. This perpetual design showed its value during the COVID-19 pandemic, when platform trials evaluated multiple treatments in sequence without restarting from scratch each time. The trade-off is governance. A structure that stays open for years must manage changing standards of care, evolving comparators, and the statistical complexity of comparing arms that entered at different times, which is why the FDA guidance devotes attention to control-arm choice and analysis planning.

How tissue-agnostic approvals arise

The through-line from design to approval runs through the basket. When a biomarker-defined population responds consistently across tumor types, the regulatory case for approving by biomarker rather than by organ becomes coherent. The evidence is often a single-arm response rate rather than a randomized survival comparison, which is why several of these clearances came through the accelerated approval pathway, with confirmatory evidence expected to follow. That is a real trade-off rather than a costless win: a biomarker-agnostic label reaches patients with rare cancers who would otherwise have no matched therapy, but it rests on smaller, non-randomized datasets that require careful reading. Knowing whether an approval came from a basket cohort, an umbrella arm, or a randomized platform tells you a great deal about how much weight the underlying evidence can bear.

This article is educational and not medical advice; treatment decisions belong with a qualified clinician who knows the individual case.